Category
GLP-1 / incretin
The incretin family — GLP-1, GIP/GLP-1 and glucagon co-agonists. This is the best-evidenced category here, anchored by approved medicines backed by large trials, alongside newer investigational agents.
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
7 peptides
Semaglutide
Human RCTOzempic, Wegovy, Rybelsus
A GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. It is the best-evidenced peptide in this library, backed by large randomised trials.
Tirzepatide
Human RCTMounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, with strong randomised-trial evidence.
Liraglutide
Human RCTVictoza, Saxenda
A daily GLP-1 receptor agonist approved for type 2 diabetes and weight management. Well evidenced but largely superseded by weekly agents.
Retatrutide
Human RCTLY3437943
An investigational triple agonist (GIP/GLP-1/glucagon) with striking weight-loss results in phase 2 trials. Not yet approved; long-term safety is still being established.
Survodutide
Human observationalBI 456906
An investigational GLP-1/glucagon dual agonist in phase 3 development for obesity and liver disease. Not yet approved.
Mazdutide
Human RCTIBI362, LY3305677
A GLP-1/glucagon dual receptor agonist that was approved in China in 2025 for weight management. It remains investigational in most other regions.
Orforglipron
Human RCTLY3502970
An orally active, non-peptide (small-molecule) GLP-1 receptor agonist. It reported positive phase 3 results in 2025 and has been submitted for regulatory review; it is not yet approved for general use.